Key result
OAC monotherapy vs OAC plus SAPT in AF and stable CAD showed no significant difference in ischemic events (HR 0.90; 95% CI 0.72-1.12) but significantly reduced major bleeding (HR 0.59).
Its licence doesn't allow us to show a copy here.
Why the study?
The optimal antithrombotic strategy in patients with AF and stable CAD remains uncertain, as individual RCTs yielded variable results and lacked power for effectiveness outcomes.
Meta-Analysis (n=4,092)
Answers are grounded in this paper and cite their sources.
Supports OAC monotherapy in AF with stable CAD; challenges routine SAPT continuation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rashedi et al. (2025) conducted a meta-analysis in Atrial fibrillation and stable coronary artery disease (n=4,092). Oral anticoagulation (OAC) monotherapy vs. OAC plus single antiplatelet therapy (SAPT) was evaluated on Composite of myocardial infarction, ischemic stroke, systemic embolism, or death (HR 0.90, 95% CI 0.72-1.12). OAC monotherapy vs OAC plus SAPT in AF and stable CAD showed no significant difference in ischemic events (HR 0.90; 95% CI 0.72-1.12) but significantly reduced major bleeding (HR 0.59).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: